Oncoradio Centre Oncogard
- Address
- lock Available on a paid plan
Digestive System Diseases
Research at Oncoradio Centre Oncogard targets cancers of the digestive tract, aiming to improve treatment effectiveness. ovarian cancer trials explore new chemotherapy schedules and immunotherapy combinations. colorectal cancer studies focus on adjuvant strategies for older patients.
- Dose-dense chemotherapy regimens
- Combination of PARP inhibitor with immunotherapy
- Biomarker-driven patient selection
- Neoadjuvant strategies for advanced disease
The site collaborates in multinational studies and emphasizes personalized medicine to tailor therapies for individual patients.
Hemic and Lymphatic Diseases
Investigations include blood‑related malignancies, seeking to expand therapeutic options. acute myeloid leukemia research evaluates novel targeted agents. myelofibrosis projects assess combination approaches after JAK‑inhibitor failure. multiple myeloma work examines MRD‑adapted treatment intensification.
- Targeted therapies for high‑risk myelodysplastic syndrome
- Novel JAK‑inhibitor combinations
- Antibody‑drug conjugates for leukemia
- MRD‑guided treatment adaptation
These efforts reflect a commitment to clinical innovation in hematologic oncology.
Male Urogenital Diseases
The department conducts trials on cancers affecting the male urogenital tract. prostate cancer studies test radioligand therapy and intensified androgen deprivation. penile carcinoma investigations compare surgical and chemotherapeutic approaches.
- Radioligand therapy for metastatic castration‑resistant prostate cancer
- Combination of androgen deprivation with novel agents
- Surgical and chemotherapeutic approaches for penile cancer
- Biomarker-driven de‑escalation strategies
The program prioritizes patient‑centered care and multidisciplinary coordination.
Neoplasms
A broad portfolio addresses solid tumors, with emphasis on innovative systemic therapies. breast cancer research spans HER2‑positive de‑escalation, ER+/HER2‑low evaluation, and CDK4/6 inhibitor sequencing. endometrial cancer trials explore immunotherapy combinations for high‑risk disease.
- HER2‑targeted de‑escalation trials
- ER+/HER2‑low therapeutic evaluation
- CDK4/6 inhibitor sequencing after endocrine resistance
- Immunotherapy in triple‑negative breast cancer
The centre integrates advanced diagnostics to refine patient selection and outcome measurement.
Pathological Conditions, Signs and Symptoms
Studies focus on molecular markers that guide treatment decisions. circulating tumor DNA is used to trigger early therapy switches, while minimal residual disease status informs transplant and maintenance strategies.
- ctDNA‑guided treatment switches
- MRD‑adapted transplant strategies
- Biomarker integration in trial design
- Safety monitoring of novel agents
This work exemplifies a move toward precision oncology across multiple tumor types.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 6 therapeutic areas and 15 of 72 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 64 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Oncoradio Centre Oncogard
lock Showing 1 of 27 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized Open-Label Study of Imetelstat Versus Best Available Therapy in Intermediate-2 or High-Risk Myelofibrosis Refractory to JAK-Inhibitors | Geron Corp. | Phase III | Not Recruiting | Apr 2021 | — |
IMP list
lock Showing 1 of 72 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Paclitaxel | 8 | Unknown | 2016-10-17 | 2026-04-29 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.